Lobe Sciences Ltd · CSE:LOBE
Lobe Sciences — Investor Presentation (September 2026)
21 slides from Lobe Sciences's investor presentation, Sep 15, 2026
Slide 1: Company Introduction
Company Introduction Lobe Sciences is a clinical stage biotech company that discovers, funds, and de-risks drug candidates for rare and underserved diseases. September 15, 2026 Dr. Frederick D. Sancilio, PhD — CEO & Chairman CSE: LOBE • OTCQB: LOBEF • FSE: LOBE.F
Slide 2: Disclaimer
Disclaimer • This pre sent at ion (“P resen ta tion ”) is an up dat e of Lo be Sc ie nc es , I nc. (t he “Com pany”) an d is f or inf orma tio n pu rposes on ly an d shou ld no t be relie d on f or t he pu rposes of makin g an invest men t de cis ion . This Pr esent at ion do es no t, an d it is no
Slide 3: Investment Highlights
Investment Highlights A capital-efficient clinical-stage biotech advancing two independent drug candidates toward licensing or partnering with larger pharmaceutical companies. • Undervalued Opportunity - Market Cap: ~$32M CAD vs. CMPS ($0.5B), ATAI ($1.0B), MNMD ($0.7B) Growth has been accretive to
Slide 4: Lobe Operates Three Therapeutically focused Subsidiaries
Lobe Operates Three Therapeutically focused Subsidiaries This presentation will primarily focus on Cynaptec’s L-130 (psilocin mucate) CSE: LOBE • OTCQB: LOBEF • FSE: LOBE.F 4
Slide 5: Current Challenges Facing the Development of Psilocybin as a Block-Buster Therapeutic
Current Challenges Facing the Development of Psilocybin as a Block-Buster Therapeutic Psilocybin is a Prodrug which Psilocybin is poorly bioavailable To overcome this, effective dose must be metabolized to Psilocin (50%) and inconsistent levels must be higher than to be active needed causing severe
Slide 6: The Problem and the Solution: Psilocybin Psilocin
The Problem and the Solution: Psilocybin Psilocin Problem: Dosing psilocybin at • The hallucinations force the use of the therapeutic to be infrequent (weekly or levels that will be consistently less frequent dosing interval) efficacious require doses that • Patients have to be observed for hours po
Slide 7: The Solution to Psilocybin's Challenges: L-130 (Psilocin Mucate)
The Solution to Psilocybin’s Challenges: L-130 (Psilocin Mucate) Delivers psilocin the active metabolite Following 129 attempts to stabilize psilocin, the mucate (L-130) was synthesized CSE: LOBE • OTCQB: LOBEF • FSE: LOBE.F 7
Slide 8: L-130 Psilocin Mucate's "First-In-Human" Study
L-130 Psilocin Mucate’s “First-In-Human” Study Published: Sancilio et al., 2024 Study Design • Single-dose Phase 1a safety study (4 mg psilocin mucate) Safety • No serious adverse events and no hallucinogenic effects at this dose Pharmacokinetics • Psilocin was rapidly absorbed after oral administra
Slide 9: Human Psilocin Exposure (Psilocybin vs Psilocin)
Human Psilocin Exposure (Psilocybin vs Psilocin) Psilocin derived from psilocybin shows broad variability; L-130 psilocin mucate shows a tighter exposure range. Psilocin After Psilocybin (10mg ) = (7mg psilocin after MW correction) Psilocin After L-130 Psilocin Mucate (4mg) = (2mg psilocin after MW
Slide 10: Can Psilocin be given on a daily, sub-hallucinogenic level and still be effective?
Can Psilocin be given on a daily, sub-hallucinogenic level and still be effective? Four independent preclinical assessments were made comparing daily versus weekly dosing. Animals were subjected to stress (CUMS*) then the impact of a human equivalent dose of ~2mg was measured as follows: • Cortisol
Slide 11: Cortisol Levels Following CUMS
Cortisol Levels Following CUMS CSE: LOBE • OTCQB: LOBEF • FSE: LOBE.F 11
Slide 12: Elevated Plus Maze
Elevated Plus Maze CSE: LOBE • OTCQB: LOBEF • FSE: LOBE.F 12
Slide 13: Open Field-Internal Zone
Open Field-Internal Zone CSE: LOBE • OTCQB: LOBEF • FSE: LOBE.F 13
Slide 14: Novel Object Recognition
Novel Object Recognition Both Daily (G4) and Weekly(G5) achieved significant results CSE: LOBE • OTCQB: LOBEF • FSE: LOBE.F 14
Slide 15: L-130 Can Create a Unique Commercial Opportunity
L-130 Can Create a Unique Commercial Opportunity Any application utilizing psilocybin can be easily reformulated with psilocin (L-130) creating broad commercial opportunity via 505b2 Psilocin (L-130) has demonstrated superior anxiolytic activity (preclinical) given daily compared to weekly dosing ex
Slide 16: Current Applications of L-130 (psilocin mucate)
Current Applications of L-130 (psilocin mucate) A Patented and New Chemical Entity and some Applications Substance Use Generalized Anxiety Cluster Headache (CH): Disorder (Addiction): Disorder (GAD): Targeting one of the most Preclinical data sugge sts GAD impacts 2.7% of U.S. severe pain conditions
Slide 17: Conjugated Psilocin Development Program
Conjugated PsilocinTM Development Program Program Status and Key Milestones Completed 2024 2025 2026 2027 2028 Patent Filings Preclinical St udies Phase 1 Safety Study Psilocin Psilocin Key Milestones (independent of Mucate Mucate indication) 28-d a y Toxicity Rodent Study Patent Patent 10-1-24 11-8
Slide 18: Introducing S-100: A Patented Treatment Of Sickle Cell Disease
Applied Lipid Introducing S-100: A Patented Treatment Of Sickle Cell Disease Technologies, Inc. • Applied Lipid Technologies, Inc. is a clinical-stage subsidiary focused on the treatment of membranopathies. • Current programs include the treatment of pediatric and adult sickle cell diseases. • Addit
Slide 19: Annualized Rate of VOCs
Vaso-occlusive Crisis (VOC) Data After 8 Applied Lipid Technologies, Inc. Weeks Of Treatment With Docosahexaenoate Active (N = 50) Placebo (N = 17) 4 3.46 3.45 3.5 3.35 3 24% Annualized Rate of VOCs 40% 2.5 1.96 2 1.5 76% 1 60% 0.5 0 Baseline Double Blind (Week 8) Baseline Double Blind (Week 8) ≤3 B
Slide 20: Upcoming Possible Inflection Points
Upcoming Possible Inflection Points Additional Patents are Expected to be Approved over the next 12 months Orphan Drug Designation granted by US FDA and the European Commission L-130 Preclinical and Clinical Research Milestones will be Announced a s Achieved Multiple IND filings 2027 - 2028 Increase
Slide 21: Thank You
Thank You Dr. Frederick D. Sancilio, PhD CEO & Chairman lobesciences.com CSE: LOBE • OTCQB: LOBEF • FSE: LOBE.F
Lobe Sciences — Investor Presentation (September 2026) on 6ix